Data protection Impressum

Pharma

WuXi AppTec has opened a new pharmaceutical production line at its site in Couvet, in the canton of Neuchâtel. The USD 100 million investment is part of a broader project to make the site a main production center in Europe for the group.

WuXi AppTec inaugurates a USD 100 million spray-drying line in Couvet

7 October 2026

A new study by BAK Economics shows that the life sciences sector generates CHF 20.6 billion in direct value added in Western Switzerland, and CHF 28.3 billion once its ripple effects across the regional economy are taken into account.

Life sciences generate CHF 28.3 billion in direct value in Western Switzerland

6 October 2026

Addex Therapeutics, the Geneva-based clinical-stage biotech developing small-molecule allosteric modulators for neurological disorders, has raised gross proceeds of USD 2.8 million through its at-the-market program.

Addex Therapeutics extends its cash runway into the fourth quarter of 2027

31 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

A new EY study ranks Switzerland 3rd worldwide for corporate R&D intensity and 6th for total spending, with 14 Swiss companies among the global top 500.

Business environment

Switzerland ranks 3rd globally for corporate R&D intensity

18 May 2026

The Swiss Biotech Report 2026 reveals record sector revenues and a landmark year for private funding, as talent and international collaboration continue to underpin Switzerland's position at the forefront of global life sciences.

Swiss Biotech Report 2026: talent and tenacity drive record performance

5 May 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (April 2026)

29 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

1 2 3 4 5 … 11